中国P站

Osteosarcoma; Immunotherapy; Immune checkpoints; PD-1; PD-L1; CTLA-4; Biomarkers; Personalized therapy; Tumor microenvironment; Precision oncology

Introduction

Osteosarcoma is a highly aggressive bone tumor that predominantly affects adolescents and young adults. It is characterized by the production of malignant osteoid and a proclivity for early lung metastasis. Standard treatment involves neoadjuvant chemotherapy, surgical resection, and adjuvant chemotherapy. Although this multimodal approach has improved survival for localized disease, metastatic and recurrent osteosarcoma continues to have a poor prognosis. In light of limited progress with traditional chemotherapeutics, there is an urgent need for novel strategies that account for the complex tumor biology of osteosarcoma [1]. The advent of immunotherapy has revolutionized treatment paradigms in several cancers, particularly through the use of immune checkpoint inhibitors (ICIs). These agents target regulatory pathways that cancer cells exploit to evade immune surveillance. However, in osteosarcoma, the efficacy of ICIs has been modest, suggesting that a one-size-fits-all approach may not be sufficient. Personalized immunotherapy, guided by specific biomarkers, may provide a new path forward. This review explores how immune checkpoints and molecular biomarkers can be leveraged to tailor osteosarcoma treatment more effectively [2].

Description

The immune landscape of osteosarcoma is characterized by a complex interplay of tumor cells, stromal components, and immune infiltrates. Despite being immunogenic in nature—evidenced by high levels of immune cell infiltration and tumor-associated antigens—osteosarcoma often escapes immune destruction through the expression of checkpoint molecules [3]. PD-1 (programmed death-1) and its ligand PD-L1 are among the most studied immune checkpoint pathways. In osteosarcoma, PD-L1 is variably expressed on tumor cells and tumor-infiltrating immune cells. High PD-L1 expression has been associated with poor prognosis, higher metastatic potential, and resistance to therapy. Similarly, CTLA-4 (cytotoxic T-lymphocyte-associated antigen 4) inhibits early T-cell activation and has been implicated in immune evasion in osteosarcoma [4]. Clinical trials investigating ICIs such as nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) have shown limited efficacy when used as monotherapy in osteosarcoma patients. This may be due to an immunosuppressive tumor microenvironment (TME), low tumor mutational burden (TMB), or the absence of predictive biomarkers to guide treatment selection [5].

Emerging biomarkers may provide the key to unlocking the potential of immunotherapy in osteosarcoma. These include:

Tumor Mutational Burden (TMB): While osteosarcoma generally exhibits a complex karyotype, it often has a relatively low TMB compared to other cancers. However, subsets of patients with high TMB may respond better to ICIs.

Immune Cell Infiltration: The presence and ratio of tumor-infiltrating lymphocytes (TILs), particularly CD8+ cytotoxic T cells, may correlate with response to immunotherapy. High infiltration of Tregs (regulatory T cells) and M2 macrophages, on the other hand, may predict resistance.

PD-L1 Expression: Immunohistochemical analysis of PD-L1 on tumor cells can stratify patients more likely to benefit from PD-1/PD-L1 blockade, though results have been inconsistent [6].

Gene Expression Signatures: Immune-related gene expression profiles, such as interferon-gamma response signatures, can identify tumors with an "inflamed" phenotype more amenable to immunotherapy.

Circulating Tumor DNA (ctDNA): Liquid biopsy approaches using ctDNA can monitor tumor dynamics, assess minimal residual disease, and provide real-time insights into treatment response.

Discussion

The integration of immune checkpoint inhibitors into osteosarcoma therapy is still in its infancy. While early-phase clinical trials have not demonstrated robust responses, they have laid the groundwork for biomarker-driven trials. One strategy gaining momentum is combination therapy, which pairs ICIs with chemotherapy, targeted agents, or oncolytic viruses to enhance immunogenicity and overcome resistance [7]. For example, chemotherapy may induce immunogenic cell death, increasing neoantigen presentation and T-cell priming. Tyrosine kinase inhibitors (TKIs), such as cabozantinib and regorafenib, may modulate the TME by reducing immunosuppressive myeloid cells. Combining TKIs with ICIs is currently under evaluation in several clinical trials for osteosarcoma [8].

Another approach involves using immune checkpoint inhibition as an adjuvant strategy post-surgery, particularly in patients with high-risk features or detectable ctDNA. This could potentially prevent relapse by targeting micrometastatic disease. Patient stratification based on predictive biomarkers is essential to maximize benefit and minimize unnecessary toxicity [9]. Integrating multi-omics approaches—combining genomics, transcriptomics, and proteomics—may provide a comprehensive view of the tumor immune milieu and identify novel therapeutic targets. Pediatric considerations are also important, as the majority of osteosarcoma patients are adolescents. The long-term safety profile of immunotherapy in this age group must be thoroughly assessed. Moreover, collaborative efforts and international consortia are needed to conduct adequately powered studies, given the rarity of the disease [10].

Conclusion

Personalizing osteosarcoma therapy through immune checkpoint modulation and biomarker-driven strategies represents a promising frontier in orthopedic oncology. While challenges remain, particularly in identifying reliable biomarkers and overcoming the immunosuppressive microenvironment, ongoing research offers hope for more effective, individualized treatments. As our understanding of tumor immunology deepens, the integration of immunotherapy into osteosarcoma care is poised to transform outcomes for patients who have historically faced limited options. Future success will depend on continued investment in translational research, innovative clinical trial design, and the implementation of precision medicine principles in routine practice.

References

1. Alhaji TA, Jim-Saiki LO, Giwa JE, Adedeji AK, Obasi EO, et al. (2015) . IJRHSS 2: 22-29.

   ,

2. Gábor GS (2005) .

3. Gbigbi TM, Achoja FO (2019) . Croatian Journal of Fisheries 77: 263-270.
4. Oladeji JO, Oyesola J (2000) . Proceeding of 5th Annual Conference of ASAN 19-22.

5. Otto G, Ukpere WI (2012) . AJBM 6:6765-6770

   , Crossref

6. Shepherd CJ, Jackson AJ (2013) . J Fish Biol 83: 1046-1066.

   , , Crossref

7. Food and Agriculture Organization of United Nations (FAO) (2009) . Rome: FAO Fisheries and Aquaculture Department.

8. Adedeji OB, Okocha RC (2011) . Veterinary Public Health and Preventive Medicine. University of Ibadan, Nigeria.

9. Food and Agriculture Organization (2010-2020a). . South Africa (2018) Country Profile Fact Sheets. In: FAO Fisheries and Aquaculture Department. Rome: FAO.
10. Digun-Aweto O, Oladele, AH (2017) . J Cent Eur Agric 18: 841-850.

    ,